The polyherbal drug (Fibrosin hr.Ceftriaxone at a lower concentration (67.91  9.42 g ml -1 ) was recovered at 24 hr post dosing from urine. This is the first report of pharmacokinetic interaction of intramuscular ceftriaxone injection and the oral polyherbal drug (which was found to be a cytochrome P450 inhibitor).
Introduction
Ceftriaxone, a third generation cephalosporin, is active against a wide range of gram negative and gram positive organisms .The drug is converted in liver to a major active metabolite i.e. ceftizoxime in goat (Sar et al, 2006; Sar et al, 2008; Sar et al, 2013) and cow (Sar et al, 2010) . Ceftizoxime, a broad spectrum third generation cephalosporin, is effective against a wide variety of aerobic/anaerobic gram positive and gram negative bacteria and remains highly stable in presence of β lactamases. The previous studies by our team suggested a typical absorptionreabsorption pattern of ceftriaxone in plasma of goat following intramammary administration at 50 mg kg -1 with 1 hr prior oral dosing of the polyherbal drug (Fibrosin ®) ) (Sar et al, 2011) and after intramuscular administration of ceftriaxone only at 50 mg kg -1 (Sar et al, 2013) .
Reabsorption of ceftriaxone was also observed following intravenous injection of ceftriaxone at 50 mg kg -1 in lactating goats with 1 hr prior oral dosing of the polyherbal drug (Fibrosin ® ) for which ceftriaxone was again available from 36 to 84 hr post dosing in plasma following its disappearance from 3 hr post dosing (Sar et al 2006) . However, reabsorption of ceftriaxone could not be observed after intravenous injection of ceftriaxone only at 50 mg kg -1 (Sar et al, 2006; Guerrini et al, 1983) . Administration of ceftriaxone at 46 mg kg -1 intravenously to sheep resulted in more rapid non-renal elimination of ceftriaxone and biliary secretion of ceftriaxone into the duodenum was reported (Arvidsson et al, 1982; Stoeckel et al, 1981) . But, reabsorption may also occur in intestine. Although the previous studies on intramuscular pharmacokinetics of ceftriaxone in cow calves (Soback et al,1988; Johal &Srivastava, 1998) , camel (Goudah, 2008) , cat (Abarellos et al, 2007) and goat ( Ismail et al, 2005) did not reveal any absorption- . Fibrosin ® inhibited cytochrome P450 in liver of goats following single oral dosing at 1.9 gm, but intravenous ceftriaxone injection at 50 mg kg -1 with 1 hr prior oral dosing of Fibrosin ® caused induction of cytochrome P450 in liver of goats (Sar et al, 2006) . Fibrosin ® enhanced the penetration of ceftizoxime through milk-blood barrier and increased the bioavailability of ceftizoxime in milk following a single dose intramammary administration of ceftriaxone at 50 mg kg -1 after its metabolism in liver (Sar et al, 2011) . Oral administration of Fibrosin ® also could be preferred with concurrent administration of intramuscular ceftriaxone for treatment of sensitive bacterial infections except mastitis as it causes zero level milk residue of ceftizoxime (Sar et al, 2014) . The polyherbal drug also returned increased milk alkaline phosphatase and catalase activity in mastitic goats to normal level and maintained normal glutathione level with significantly increased lactoperoxidase activity with 1 hr prior oral administration to single intravenous dosing of ceftriaxone (Sar et al, 2012) . The polyherbal drug also protected mammary gland from tissue damage caused by intramammary administration of ceftriaxone (Sar et al, 2015) . Milk alkaline phosphatase and catalase activity and reduced glutathione level did not differ significantly between healthy and fibrosin treated goats following single intramuscular dosing of ceftriaxone without and with 1 hr prior oral administration of Fibrosin ® (Sar et al, 2014) . Disposition of ceftriaxone exhibited absorption-reabsorption pattern in healthy goats, while it was absent in carbontetrachloride treated hepatopathic and no reabsorption in uranyl nitrate treated nephropathic goats following single intramuscular and intravenous dosing and at50 mg kg -1 (Sar et al, 2013) . Ceftriaxone was reported to induce cytochrome P450 in liver and the polyherbal drug (Fibrosin ® ) was found to inhibit cytochrome P450 (Sar et al, 2006) . Disposition of ceftriaxone in healthy goats following single intramuscular dosing at 50 mg kg -1 had already been reported (Sar et al, 2013) .
Therefore, the present study was aimed to evaluate disposition kinetics of ceftriaxone in presence of the polyherbal drug (Fibrosin ® ) and to observe its effect on intestinal reabsorption of ceftriaxone following single intramuscular administration of ceftriaxone with 1 hr prior oral dosing of Fibrosin ® as the polyherbal drug was found to inhibit cytochrome P450 oxidase system in liver. The study was also conducted to explore possible pharmacokinetic interactions between intramuscular ceftriaxone injection and any cytochrome P450 inhibitor drug.
Results
The recovery percentage of ceftriaxone and ceftizoxime were 81.14±4.95% and 80.37±2.30%, respectively in plasma. In urine, the recovery percentage of ceftriaxone and ceftizoxime were 85.83±4.21% and 87.56±2.84%, respectively. The chromatograms of standard ceftriaxone and ceftizoxime were presented in Figure 1 Ceftriaxone at a concentration of 67.91  9.42 g ml -1 was recovered at 24 hr post dosing from urine of the lactating goats. However, neither ceftriaxone nor ceftizoxime (active metabolite of ceftriaxone) could be detected in urine at 48 and 72 hr post dosing.
Discussion
Single dose oral administration of Fibrosin ® (1.9 gm) did not change Icterus index, serum bromosulphophthalein clearance (BSP), serum aspartate transaminase activity (AST) and serum alanine transaminase activity (ALT) significantly (p<0.05) between different days (0, 3 and 7) which indicated that Fibrosin ® does not alter normal liver functions.
Plasma concentration of ceftriaxone showed an increasing -decreasing pattern followed by the same increasing-decreasing pattern again in lactating goats following single intramuscular dosing with 1 hr prior oral administration of Fibrosin ® ( Table 2) (Table 3) . Hepatic clearance of ceftriaxone predominated renal clearance in goats (Sar et al, 2008) . Ceftriaxone was found to be an inducer of microsomal cytochrome P450 in liver and undergoes hydrolysis to produce its active metabolite i.e. ceftizoxime through cleavage of thioether bond present in ceftriaxone (Sar et al, 2006) . Furthermore, ceftrixone having a molecular weight 554.59 is liable to excrete through bile that may undergo reabsorption in the intestine resulting in its entry into the systemic circulation followed by metabolism in liver (Sar et al, 2011; Sar et al, 2013) or reabsorption again. Therefore, biphasic increased concentration of ceftriaxone after intramuscular administration in these animals may suggest enterohepatic circulation of ceftriaxone and its intestinal reabsorption in goats.
Ceftriaxone persisted for 3 hr in plasma of lactating goats following single intramuscular dosing at 50 mg kg -1 with 1 hr prior oral administration of Fibrosin ® in the present study while it persisted for 2 hr in lactating goats without the polyherbal drug (Sar et al, 2013) .The Ka(absorption rate constant) of ceftriaxone in presence of the polyherbal drug was 10.75  0.80 hr -1 (Table 3) in the present study which increased markedly compared to Ka value of 8.41 0.02 hr -1 in healthy goats without oral administration of the polyherbal drug (Sar et al, 2013) .It indicated that the polyherbal drug has increased the absorption rate of ceftriaxone from intramuscular site as well as the persistence of the drug in the body. Moreover, it can be transpired that Fibrosin ® , an inhibitor of cytochrome P450 oxidase system may cause lesser/negligible metabolism of ceftriaxone through this system leading to longer persistence compared to healthy goats without fibrosin administration.
Ceftriaxone persisted for 2hr in plasma in healthy goats following single intramuscular dosing at 50 mg kg -1 and showed a reabsorption half life (t½Ka) of 0.09  0.005 hr (Sar et al, 2013) . But it persisted for a longer time in fibrosin treated goats which might be due to its enhanced intestinal reabsorption and impaired metabolism in liver compared to healthy goats which is also evidenced by its two fold increased half life of reabsorption (t½Ka=0.18  0.003 hr) (Table 3) . Ceftriaxone also showed reabsorption following enterohepatic circulation in healthy goats after intramammary administration of ceftriaxone with 1 hr prior oral dosing of (Sastry, 1999) . Ceftriaxone, being a lipid soluble drug may be absorbed in presence of bile from the intestine. Failure of bile excretion due to hepatic damage was responsible either for accumulation of drug in the liver or interference with the further absorption of ceftriaxone resulting in absence of reabsorption phase in the disposition of the drug in hepatopathic goats (Sar et al, 2013) .Ceftriaxone showed major hepatic clearence in goats which was evidenced by its higher ClH value (Sar et al, 2008) and intestinal reabsorption of ceftriaxone occurred in the present study following intramuscular administration which indicated that the polyherbal drug did not interfere with bile secretion from liver and caused enhanced excretion of ceftriaxone through bile. The t½k (elimination half life) of ceftriaxone was 0.43  0.035 hr with prior oral administration of the polyherbal drug in the present study. But it decreased drastically compared to t½k value of 0.76  0.09 hr in healthy goats following intramuscular dosing of ceftriaxone at the same dose rate without Fibrosin ® administration (Sar et al, 2013 ) which may be due to enhanced excretion of the drug through bile. No reabsorption phase could be observed in disposition of ceftriaxone in previous studies by other research workers in healthy animals after intramuscular administration which might be due to collection of blood samples at comparatively longer intervals. Blood samples from fibrosin treated lactating goats were collected at comparatively shorter intervals from our previous experience during the study (Sar et al, 2013 ).
Ceftizoxime could not be detected in urine of fibrosin treated healthy goats which further suggested negligible metabolism of ceftriaxone leading to non-availability of its metabolite, ceftizoxime. It is reported that ceftriaxone induces cytochrome P450 in liver and undergoes hydrolysis to form the major active metabolite i.e. ceftizoxime following single dose intravenous and intramuscular administration at 50 mg Kg -1 in goats which was excreted at higher concentration in urine up to 72 hr of collection (Sar et al, 2006; Sar et al, 2013) . Oral Fibrosin ® administration may decrease the content of cytochrome P450 which is responsible for impaired metabolism of ceftriaxone in healthy goats resulting in non availability of its metabolite in urine. Ceftriaxone is mixed function oxidase system inducer causing more formation of its own metabolite (ceftizoxime) which is expected to excrete through urine in healthy goats. But ceftriaxone has lesser/no effect on MFO system in presence of fibrosin resulting in negligible amount of metabolite formation which might be the reason of non availability of ceftizoxime in urine of fibrosin treated goats. Ceftriaxone is inducer of hepatic microsomal enzyme systems while fibrosinis the inhibitor of the enzyme and combined therapy induced enzyme activity (Sar et al, 2006) . Interestingly, combined therapy of intramuscular ceftriaxone injection and oral 
Materials and Methods

Drugs and Chemicals
Ceftriaxone (analytical grade, purity ≥ 90 %;Estral Pharmaceutical Industries, Vadadora, Gujarat, India) was used as test drug. Ceftizoxime (analytical grade, purity ≥ 90 %) was obtained active principles present in these plants were presented in our earlier studies (Sar et al, 2006; Sar et al, 2011) . Fibrosin ® was used as ctochomeP450 inhibitor for pharmacokinetic interaction study with intramuscular ceftriaxone injection.
Animals
A total of 6 apparently healthy lactating goats weighing between 10-12 kg of approximately 1½-2 years of age were used in this experiment. The animals were caged individually in custom made metabolic cages (stainless steel) during experimental period.
Artificial lighting facility was provided with 12 hour dark period. Animals were stall-fed and the standard feed as well as water was provided ad libitum.The composition of the feed was 2 parts wheat husk, 1 part groundnut cake, 1 part crushed gram, 1 part crushed maize, and 2 parts greens. The animals were dewormed with a single oral dose of rafoxanide at 7.5 mg kg -1 body weight 30 days prior to the onset of study. Before the start of the experiment, the animals were acclimatized for 7 days.
Experimental design
The effects of Fibrosin ® in liver of six healthy lactating goats were assessed by performing icterus index, serum bromosulphophthalein clearance (BSP), serum aspartate transaminase activity (AST), serum alanine transaminase activity (ALT). For this study, a half bolus of Fibrosin ® (1.9 gm) was administered orally making suspension in 50 ml distilled water to each lactating goat and the tests were performed collecting serum before oral dosing of Fibrosin ® and on day 3 and 7 after Fibrosin ® administration.
For pharmacokinetic interaction study, a single dose of ceftriaxone dissolving in 5 ml of distilled water was administered at 50 mg kg -1 body weight to each animal deep at thigh muscle.
A half bolus of fibrosin (1.9 gm) was administered orally to each goat before 1 hr of ceftriaxone administration making suspension in 50 ml distilled water. The same animals were utilized for pharmacokinetic interaction study after allowing a washing period of 1month. 
Biochemical tests
Bromosulphophthalein (BSP) clearance test
The test was carried out in the serum of goats before administration of fibrosin ® (1.9gm) and on day 3 and 7 and bromosulphophthalein (BSP) clearance (Varley et al, 1975) was expressed as t½ min (elimination half life).
Icterus index
The test was carried out in the serum of goats 17 at '0' (pre dosing of fibrosin ® ), day 3 and 7 following oral administration of fibrosin ® and was expressed as unit.
Estimation of serum AST and ALT activity
Serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) activities were measured according to the method of Yatazidis (Yatazidis, 1960) .
Analysis of ceftriaxone and ceftizoxime
Extraction of ceftriaxone as well as its metabolite, ceftizoxime from plasma and urine was done which were subsequently analyzed by HPLC. Plasma or urine (0.5 ml) was taken in a test tube, 0.5 ml of mobile phase was added to it. After that 2 ml of the mixture containing 70% methanol, sodium acetate (30% of 0.1M) added to the test tube to make a total volume of 3 ml and pH (5.2) was adjusted by using HPLC grade acetic acid (1-2 drops). The mixture was vortexed for 30 minute and incubated at 4 0 C for 15 min. The whole aliquot was centrifuged at 3000 rpm for 15 min. and supernatant was collected after passing through a filter paper 
Pharmacokinetic analysis
The concentration of ceftriaxone in plasma of lactating healthy goats at different time intervals was plotted on a semilogarithmic paper and the pharmacokinetic parameters were analysed by non-compartmental method. The initial increased concentration was considered as absorption phase (Ka) which was followed by decreased concentration and considered as distribution phase (K). The concentration increased again considered as reabsorption phase (K´a) followed by decreased concentration considered as elimination phase (K´). All these half-lives were calculated from the same graph and AUC (area under curve) was determined based on trapezoid method. The other pharmacokinetic parameters were determined as per the method of Baggot (Baggot, 1977) . The pharmacokinetic parameters such as K, K´, Ka, K´a are indicated for K distribution rate constant, K´ elimination rate constant, Ka absorption rate constant, K´a reabsorption rate constant in healthy lactating goats in which pharmacokinetic profile of ceftriaxone showed a distinct reabsorption phase.
Statistical analysis
The results were expressed as Mean ± Standard error (S.E.). The data were analyzed statistically using general linear model with univariate data in SPSS 10.0 version of software (students's t test). 
